Shah M, Osgood CL, Amatya AK, Fiero MH, et al. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple Negative Breast Cancer. Clin Cancer Res 2022 Aug 4. pii: 707438. doi: 10.1158/1078-0432.CCR-22-1110.
PMID: 35925043